Including mRECIST in the Metroticket 2.0 criteria improves prediction of hepatocellular carcinoma-related death after liver transplant.
Cucchetti A, Serenari M, Sposito C, Di Sandro S, Mosconi C, Vicentin I, Garanzini E, Mazzaferro V, De Carlis L, Golfieri R, Spreafico C, Vanzulli A, Buscemi V, Ravaioli M, Ercolani G, Pinna AD, Cescon M.
Cucchetti A, et al. Among authors: pinna ad.
J Hepatol. 2020 Aug;73(2):342-348. doi: 10.1016/j.jhep.2020.03.018. Epub 2020 Mar 20.
J Hepatol. 2020.
PMID: 32201284
Free article.